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The purpose of the present study was to study the impacts of eplerenone (EPL), an antagonist of mineralocorticoid receptors 
(MR), on atrial fibrosis in a mouse model with selective fibrosis in the atrium, and to explore the possible mechanisms. Using 
mutant TGF-1 transgenic (Tx) mice, we first demonstrated that EPL inhibited atrial fibrosis specifically and decreased mac-
rophage accumulation in the atria of these mice. Results from immunohistochemistry and western blotting showed that EPL 
attenuated protein expression of fibrosis-related molecules such as connective tissue growth factor (CTGF) and fibronectin in 
the atria of Tx mice. In culture, EPL inhibited gene expression of fibrosis-related molecules such as fibronectin, -SMA, and 
CTGF in TGF-1-stimulated atrial fibroblasts. Finally, using a co-culture system, we showed that TGF-1-stimulated atrial fi-
broblasts induced migration of macrophages and this was blocked by EPL. EPL also blocked TGF-1-induced gene expression 
of intedeukin-6 (IL-6) in atrial fibroblasts. Therefore, we conclude that EPL attenuated atrial fibrosis and macrophage infiltra-
tion in Tx mice. TGF-1 and IL-6 were involved in the impacts of EPL on activation of atrial fibroblasts and interactions be-
tween fibroblasts and macrophages. 
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Atrial fibrillation (AF) is the most common type of  
arrhythmia in clinical practice and posts great challenges to 
medical treatment (Allessie et al., 2002; Nattel, 2002). Atri-
al fibrosis is a hallmark of atrial structural remodeling that 
critically contributes to the occurrence and maintenance of 
AF (Burstein and Nattel, 2008). Therefore, targeting atrial 
fibrosis is an important strategy to treat AF.  
Renin-angiotensin-aldosterone system plays important 
roles in atrial fibrosis (Ehrlich et al., 2006; Mayyas et al., 
2013). Various drugs have been used in clinics to block this 
system. However, long-term therapeutic effects are not sat-
isfactory, likely because of the failure to reduce production 
of aldosterone, the endogenous agonist of mineralocorticoid 
receptors (MR) (Struthers, 2004; Ehrlich et al., 2006; Duan, 
2014). MR antagonists have been shown to inhibit atrial 
fibrosis in animal models such as myocardial infarction that 
is accompanied by ventricular fibrosis (Milliez et al., 2005). 
It has remained unclear whether the impacts of MR antago-
nists on the atrium are dependent on the ventricular  
changes. 
Fibroblasts and transforming growth factor-1 (TGF-1) 
are essential in atrial fibrosis (Burstein and Nattel, 2008). 
Activated TGF-1 and angiotensin II promote the produc-
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tion of each other and both induce fibrosis-related mole-
cules in fibroblasts, contributing to atrial fibrosis (Burstein 
and Nattel, 2008; Zhang et al., 2015b). Our previous study 
has shown that in the presence of angiotensin II, activated 
fibroblasts induces the infiltration of macrophages that in 
turn promote the proliferation of fibroblasts (Chen et al., 
2015b). However, the impacts of MR antagonists on fibro-
blasts and their interactions with macrophages are not com-
pletely understood. 
In the current study, we aim to investigate the effects of 
MR antagonist on atrial fibrosis and macrophages infiltra-
tion using MHC-transforming growth factor (TGF)- 
1cys33ser transgenic (Tx) mice that have fibrosis in atria 
selectively and to explore the underlying mechanisms. 
RESULTS 
EPL inhibits atrial fibrosis and macrophages infiltration 
To investigate whether EPL specifically suppresses atrial 
fibrosis, we treated Tx mice with EPL diet. Masson’s tri-
chrome staining demonstrated that untreated Tx mice had 
significant atrial fibrosis and this was markedly suppressed 
by EPL treatment (Figure 1A and B). We have previously 
shown that macrophages are involved in the process of atrial 
fibrosis (Chen et al., 2015b). Thus, we used MAC2 to detect 
macrophages in atria. The results showed that Tx mice had 
more infiltrated macrophages in atria than wild type mice 
and that EPL treatment significantly inhibited macrophage 
infiltration in the atria of Tx mice (Figure 1C and D). 
EPL suppresses fibrosis-related molecules in atria 
To further analyze the pathological consequences, we next 
examined protein levels of fibrosis-related molecules in 
atria. Results from both immunohistochemistry and western  
blotting showed that EPL attenuated expression of CTGF 
and fibronectin in the atria of Tx mice (Figure 2), further 
demonstrating the inhibitory effects of EPL on atrial   
fibrosis. 
EPL suppresses expression of fibrosis-related genes in 
fibroblasts 
We next examined expression of fibrosis-related genes in 
primary atrial fibroblasts. TGF-1 markedly increased the 
expression of fibronectin, -smooth muscle actin (-SMA) 
and CTGF, all of which have been shown to play important 
roles in atrial fibrosis (Figure 3). EPL significantly attenu-
ated TGF-1-induced expression of these genes and it did 
not affect the expression in un-stimulated fibroblasts at 
baseline (Figure 3). 
EPL inhibits fibroblasts-induced macrophage migration 
Finally, we investigated the impacts of EPL on interactions 
between atrial fibroblasts and macrophages using a 
co-culture system. Transwell assay showed that when 
co-cultured with TGF-1-stimulated atrial fibroblasts, more 
migration of macrophages was observed, whereas EPL sig-
nificantly suppressed macrophage migration (Figure 4A and 
B). Furthermore, TGF-1 increased IL-6 gene expression of 
atrial fibroblasts in the co-culture system and such elevation 
was blocked by EPL (Figure 4C). These results implied that 
IL-6 might be involved in the suppressive effects of EPL on 
fibroblast-macrophage interactions and then macrophage 
migration. In co-culture system using un-stimulated fibro-
blasts, EPL alone did not affect migration of macrophages 
or IL-6 expression of fibroblasts (Figure 4B and C). 
 
 
Figure 1  Eplerenone (EPL) inhibits atrial fibrosis and macrophage infiltration in TGF-transgenic mice (Tx). A, Representative Masson’s trichrome 
staining of atrial samples. Fibrotic areas stained blue. Scale bar, 1,500 m. B, Quantification of atrial fibrosis. C, Representative immunofluorescence stain-
ing of macrophages using MAC2 in atrial samples. Scale bar, 200 m. D, Quantification of MAC2 positive macrophages. Data are presented as mean±SEM. 
*, P<0.05; **, P<0.01; ***, P<0.001. 
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Figure 2  Eplerenone (EPL) inhibits expression of fibrosis-related molecules in atria of TGF-transgenic mice (Tx). A, Representative immunohisto-
chemical staining of CTGF in atrial samples. Positive areas stained brown. B, Quantification of CTGF positive areas. C, Representative immunohistochemi-
cal staining of fibronectin in atrial samples. Positive areas stained brown. D, Quantification of fibronectin positive areas. E, Western blotting analysis of 
CTGF and fibronectin in atrial samples. F, Quantification of CTGF detected by western blotting. G, Quantification of fibronectin detected by western blot-
ting. Scale bars, 100 m. Data are presented as mean±SEM. *, P<0.05; **, P<0.01; ***, P<0.001. 
 
Figure 3  Eplerenone (EPL) inhibits fibrosis-related gene expression induced by TGF-1 in fibroblasts. Primary atrial fibroblasts were treated with vehicle 
(DMSO), EPL, TGF-1, or TGF-1+EPL. Gene expression of fibronectin (A), -SMA (B), and CTGF (C) was measured using QRT-PCR. Data are pre-
sented as mean±SEM. *, P<0.05; ***, P<0.001. 
DISCUSSIONS 
Our results demonstrated that EPL inhibited fibrosis, mac-
rophage infiltration, and expression of fibrosis-related mol-
ecules in atria of mice that expressed constitutively active 
TGF-1. EPL suppressed TGF-1-induced expression of 
fibrosis-related molecules in atrial fibroblasts in vitro. 
TGF-1-sitmulated fibroblasts induced macrophage migra-
tion and this was blocked by EPL. Finally, TGF-1 induced 
IL-6 expression was also inhibited by EPL in atrial fibro-
blasts. 
Evidence supports that MR antagonists are beneficial for 
AF. Spironolactone, an MR antagonist, has been demon-
strated to prevent re-occurrence of AF in patients with nor-
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Figure 4  Eplerenone (EPL) inhibits fibroblasts-induced macrophage migration. A, Representative staining of macrophages in Transwell assay. Primary 
atrial fibroblasts were first stimulated with vehicle (DMSO), EPL, TGF-1, or TGF-1+EPL, and then cultured in regular media in bottom chambers of 
Transwell plates. Macrophages were subsequently added to inserts of the Transwell plates. Scale bar, 400 m. B, Quantification of macrophage migration. C, 
IL-6 gene expression detected by QRT-PCR in fibroblasts. Data are presented as mean±SEM. *, P<0.05; **, P<0.01. 
mal left ventricular systolic function (Dabrowski et al., 
2010). EPL has been shown to reduce the incidence of new 
onset of AF in patients with systolic heart failure (Swedberg 
et al., 2012). In addition, spironolactone attenuates structur-
al remodeling of the atria and improves atrial electrical  
remodeling in long-term rapid pacing-induced AF dog 
model (Zhao, 2010). Our results showed that EPL reduced 
atrial fibrosis in TGF-1 transgenic mice, further supporting 
the beneficial effects of MR antagonists in AF. 
Our results suggest that EPL inhibits atrial fibrosis 
through interfering with TGF-1signaling. First, the in vivo 
data showed that EPL inhibited atrial fibrosis mice that  
expressed constitutively active form of TGF-1. Second, 
the in vitro data demonstrated that EPL inhibited TGF-1- 
induced expression of fibrosis-related molecules in fibro-
blasts. These results imply that MR antagonist may inhibit 
atrial fibrosis via its suppression on TGF-1 signaling and 
expression of fibrosis-related molecules. Consistently,  
spironolactone has been shown to suppress aldosterone- 
induced expression of fibrosis-related molecules in fibro-
blasts (Lavall et al., 2014). A recent report has demonstrated 
that MR deficiency in endothelial cells prevented Western 
diet-induced profibrotic signaling (TGF-1/Smad pathway) 
in cardiac ventricles (Jia et al., 2015), suggesting that endo-
thelial MR directly impacts TGF-1/Smad pathway. It is 
plausible that MR affects this pathway and mediates the 
effects of EPL in atrial fibroblasts and ultimately affects 
atrial fibrosis. However, this remains to be further delineat-
ed in future investigations. 
Our study showed that EPL blocked interactions between 
fibroblasts and macrophages under stimulation of TGF-1 
and IL-6 may be involved. Infiltrated macrophages in the 
heart release various pro-inflammatory cytokines to interact 
with other cells, leading to cardiac remodeling (van 
Amerongen et al., 2007; Ma et al., 2012). Macrophages are 
important in triggering the differentiation of fibroblasts into 
myofibroblasts mainly through TGF-1-dependent path-
ways (Wynn, 2007). IL-6 has been independently related to 
cardiovascular events and death in AF patients (Roldan et 
al., 2012; Aulin et al., 2015). In addition, IL-6 plays an  
important role in the recruitment and survival of macro-
phages (Kothari et al., 2014). These findings and our results 
together suggest that interactions between macrophages and 
fibroblasts are critical in the process of atrial fibrosis and 
that a TGF-1/IL-6 axis may mediate the impacts of EPL on 
such interactions. 
The current study has several limitations. First, the exact 
function of infiltrated macrophages was not delineated in 
vivo. Second, it remains to be further determined whether 
IL-6 mediated the interactions between fibroblasts and 
macrophages as well as macrophage migration both in vivo 
and in vitro. These aspects are worth more investigations in 
the future. 
In short, we provided evidence that EPL inhibited fibro-
sis, macrophage infiltration, and fibrosis-related molecules 
in atria of mice with selective atrial fibrosis. Further, 
TGF-1 and IL-6 might be part of the mechanisms through 
which EPL suppressed fibroblast activation and fibro-
blast/macrophage interactions as well as ultimately atrial 
fibrosis. 
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MATERIALS AND METHODS 
Animal studies 
We used 3.5 months old male mice in our study (n=5 per 
group). Tx mice with selective atrial fibrosis were generated 
as previously described (Nakajima et al., 2000). Littermate 
wild type (Wt) mice were used as controls. Eplerenone 
(EPL, 200 mg kg1 day1) was mixed in mouse chow 
(Purepharm, Zhejiang). At day 75, all animals were eu-
thanized and hearts were collected and fixed in 4% para-
formaldehyde solution. All animal studies were approved by 
the Institutional Animal Care and Use Committee of Insti-
tute for Nutritional Sciences, Shanghai Institutes for Bio-
logical Sciences, Chinese Academy of Sciences. 
Histological analysis 
Fixed cardiac samples were cut into 5 m sections. Masson 
trichrome (Sigma, St. Louis, USA) were used to stain fi-
brotic areas in atria. The ratio of atrial fibrosis area to total 
atrial area was calculated. For immunohistochemistry, sec-
tions were stained with antibody against CTGF (1:200, 
Santa Cruz, USA) or fibronectin (1:200, Abcam, UK). Im-
ages were captured using Olympus microscope attached to a 
computerized imaging system and analyzed by Image-Pro 
Plus 5.0. For immunofluorescence, sections were stained 
with antibody against MAC2 (1:250, eBioscience, USA) 
and 4′,6-diamidino-2-phenylindole (DAPI) (1:1, Life tech-
nologies, USA) was used to detect nuclei. Fluorescent sig-
nals were captured by a fluorescence microscope and five 
images were randomly chosen for quantification of macro-
phages. 
Cell culture 
Atrial fibroblasts were isolated from C57BL/6J mice (Chen 
et al., 2015a) and then cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) -F12 supplemented with 20% 
fetal bovine serum in a 37°C humidified incubator with 5% 
CO2. The media were replaced every 2 days. Cells were 
cultured in DMEM-F12 with 1% serum for 24 h and then 
stimulated by TGF-1 (5 ng mL1, Pepro tech, USA) for  
24 h. In EPL group, fibroblasts were pre-treated with EPL 
(20 μmol L1, Abcam, USA) for 2 h then treated with con-
tinued EPL or TGF-1+EPL. 
To isolate primary macrophages, C57BL/6J mice were 
injected intraperitoneally with 1 mL sterile 10% thioglycol-
late medium (Scharlaus, Spain). Three days later, macro-
phages were collected by intraperitoneal lavage and cul-
tured as previously described (Usher et al., 2010). 
Quantitative RT-PCR (qRT-PCR) 
qRT-PCR was performed as we previously described 
(Zhang et al., 2015a). Primers sequences are: fibronectin, 
5′-GAAGGTTTGCAACCCACTGT-3′ (forward), 5′-TCT- 
GCAGTGTCGTCTTCACC-3′ (reverse), -smooth muscle 
actin (-SMA), 5′-ACAGAGGCACCACTGAACCCT- 
AAG-3′ (forward), 5′-ACAATCTCACGCTCGGCAGT- 
AGTC-3′ (reverse); Connective tissue growth factor 
(CTGF), 5′-GGGCCTCTTCTGCGATTTC-3′ (forward), 5′- 
ATCCAGGCAAGTGCATTGGTA-3′ (reverse); IL-6, 5′- 
GAGGATACCACTCCCAACAGACC-3′ (forward); 5′- 
AAGTGCATCATCGTTGTTCATACA-3′ (reverse); 18S, 
5′-TTGATTAAGTCCCTGCCCTTTGT-3′ (forward), 5′- 
CGATCCGAGGGCCTCACTA-3′ (reverse). 
Western blotting analysis 
Proteins were extracted from mouse atria and underwent 
western blotting analysis as previously described (Chen et 
al., 2015a). Primary antibodies are: CTGF (1:500, Santa 
Cruz), fibronectin (1:1000, Abcam), and tubulin (1:5000, 
Sigma, St. Louis). 
Transwell assay 
Fibroblasts were plated in the bottom chamber of 24-well 
plates and incubated at 37°C with 5% CO2 overnight. After 
being cultured in 1% serum medium for 24 h, fibroblasts 
were stimulated by EPL, TGF-1 or TGF-1+EPL. After 
another 24 h, the medium was changed to 1% serum medi-
um without TGF-1 or EPL. At the same time, mouse peri-
toneal macrophages were harvested and added (1×105 cells 
mL1) into transwell inserts with polycarbonate membranes 
(8.0 µm pores, Millipore, USA). Macrophages were allowed 
to migrate for 24 h in medium containing 1% serum at 
37°C. After staining, 5 high power fields (×200) were 
counted to determine the average numbers of migrated 
macrophages per high power field.  
Statistical analysis 
Statistical analysis was performed by Graphpad Prism 5 
software. The data were expressed as means±SD. The dif-
ferences between groups were assessed by one-way 
ANOVA. A value of P<0.05 was considered statistically 
significant. 
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